In a nutshell The study investigated the effectiveness of a self-management program on antiemetic-induced constipation in breast cancer patients. The study concluded that the self-management program was effective for relieving the symptoms of constipation during chemotherapy. Some background Breast cancer patients may decide to take antiemetic...
Read MoreIn a nutshell This study looked at risk factors associated with the prognosis of triple negative breast cancer patients who received neoadjuvant therapy. This study concluded that lymph node status after neoadjuvant therapy is the major prognostic factor for these patients. Some background Triple negative breast cancer (TNBC) is a type of cancer...
Read More
In a nutshell This study investigated the risk factors for recurrence in breast cancer patients treated with mastectomy without radiation therapy. The study concluded that by using these risk factors, a subgroup of patients could be defined as being at a high risk for recurrence and most likely to benefit from post-mastectomy radiotherapy (PMRT). Some...
Read More
In a nutshell This analysis examined long-term outcomes for patients with ductal carcinoma in situ (DCIS) who received different treatments. The authors concluded that in those undergoing breast conserving surgery, cancer recurrence was significantly lower when two (rather than one) additional therapies were given. Some background Ductal...
Read More
In a nutshell This study looked at the association between physical activity after a diagnosis of breast cancer and breast cancer survival. The study concluded that excercise following diagnosis was associated with a decreased risk of death in breast cancer patients. Some background Greater physical activity has been linked with decreased risk of...
Read More
In a nutshell This trial evaluated the safety and effectiveness of the drug lapatinib (Tykerb) when used in combination with other chemotherapeutic drugs to treat women with metastatic HER2 positive breast cancer. This study concluded that lapatinib combined with vinorelbine or gemcitabine were effective in these...
Read More
Cognitive side effects to chemotherapy, often called “chemobrain” or “chemofog”, are a growing concern among cancer survivors. Symptoms such as a decline in memory, concentration and executive functions (such as organization or attention) are often described. Cognitive changes can cause significant distress and prevent a return to...
Read More
In a nutshell This study explored factors that could predict disease progression following chemotherapy in breast cancer patients. The authors found that while survival rates were excellent following treatment, patients with faster-growing tumors and those with the luminal B/HER negative or triple negative subtypes had a higher risk of disease...
Read More
In a nutshell This study examined the long-term safety of everolimus (Afinitor). Everolimus treatment was found to be safe, with adverse (negative) events that were managed by reducing treatment dosage, or breaking treatment for several weeks. Some background Everolimus is a therapy that slows cancer cell growth and increases cell death. In a...
Read More![What’s Next? Side Effects of Breast Cancer Treatment [Infographic]](https://medivizor.com/blog/wp-content/uploads/et_temp/After-Treament-w-text640X320-213481_480x240.jpg)
The American Cancer Society and the American Society of Clinical Oncology have joined forces to build guidelines that can be used to treat survivors of breast cancer by primary care physicians. This is great news because there hasn’t been any standardized follow-up for those breast cancer patients that have undergone surgery, radiation and...
Read More
In a nutshell These guidelines offer recommendations for the long-term follow-up and care of breast cancer survivors. Some background The 5-year survival rate for breast cancer is currently close to 90%. Thanks to early diagnosis and care, an ever-increasing number of patients are surviving for long periods of time following treatment. Therefore,...
Read More
In a nutshell This study examined the effectiveness of palbociclib (Ibrance) in the treatment of hormone receptor-positive breast cancer patients. The authors found that palbociclib treatment increased progression free survival. Some background Major treatment options for hormone receptor-positive (HR+, dependent on the hormones estrogen and/or...
Read More
